LNA-mediated microRNA silencing in non-human primates
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
microRNAs (miRNAs) are small regulatory RNAs that are important in development and disease and therefore represent a potential new class of targets for therapeutic intervention. Despite recent progress in silencing of miRNAs in rodents, the development of effective and safe approaches for sequence-specific antagonism of miRNAs in vivo remains a significant scientific and therapeutic challenge. Moreover, there are no reports of miRNA antagonism in primates. Here we show that the simple systemic delivery of a unconjugated, PBS-formulated locked-nucleic-acid-modified oligonucleotide (LNA-antimiR) effectively antagonizes the liver-expressed miR-122 in non-human primates. Acute administration by intravenous injections of 3 or 10 mg kg(-1) LNA-antimiR to African green monkeys resulted in uptake of the LNA-antimiR in the cytoplasm of primate hepatocytes and formation of stable heteroduplexes between the LNA-antimiR and miR-122. This was accompanied by depletion of mature miR-122 and dose-dependent lowering of plasma cholesterol. Efficient silencing of miR-122 was achieved in primates by three doses of 10 mg kg(-1) LNA-antimiR, leading to a long-lasting and reversible decrease in total plasma cholesterol without any evidence for LNA-associated toxicities or histopathological changes in the study animals. Our findings demonstrate the utility of systemically administered LNA-antimiRs in exploring miRNA function in rodents and primates, and support the potential of these compounds as a…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, some reports have shown that an anti-microRNA antisense oligonucleotide efficiently blocked the function of the microRNA, thereby alleviating diseases in rodents and nonhuman primates (29,30).”
From ZFP36L1 and ZFP36L2 control LDLR mRNA stability via the ERK–RSK pathway (2014) · cites this paper as [29]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766
Cited by
Items 501–600 of 1,004
MicroRNA dysregulation in neuropsychiatric disorders and cognitive dysfunction
Xu, B., Hsu, P.-K., Karayiorgou, M., & Gogos, J. A. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.02.016 · Cited by 89
MicroRNAs regulating lipid metabolism in atherogenesis
Rayner, K. J., Fernandez-Hernando, C. F., & Moore, K. J. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-10-0694 · Cited by 89
Prognostic markers and putative therapeutic targets for hepatocellular carcinoma
Frau, M., Biasi, F., Feo, F., & Pascale, R. M. (2010) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2010.02.007 · Cited by 81
Small non-coding RNA therapeutics for cardiovascular disease
Shah, A. M., & Giacca, M. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac463 · Cited by 100
“An effective modification to increase stability of ASOs is the inclusion of RNA nucleotides in which the ribose moiety contains an extra bond between the 2′ oxygen and 4′ carbon (2′-O,4′-C-methylene bridge).(9) These locked nucleic acid (LNA) nucleotides confer remarkable thermal stability against enzymatic degradatio…”
BackgroundThe role of microRNAs in chronic respiratory disease: recent insights
Stolzenburg, L. R., & Harris, A. (2017) · Biological Chemistry · doi:10.1515/hsz-2017-0249 · Cited by 92
“Systemically injected LNA-antimiRs naturally accumulate in the liver, and were found to deplete miR-122 levels and improve liver function in both mice and primates (Elmén et al., 2008a,b).”
Gori, M., Arciello, M., & Balsano, C. (2014) · BioMed Research International · doi:10.1155/2014/741465 · Cited by 84
“For all these reasons,miR-122 has been suggested as a possible therapeutic target in the treatment of hypercholesterolemia in humans [44], such that it is in phase I clinical trials for treating dyslipidemia [42].”
BackgroundMurray, S., Ittig, D., Koller, E., Berdeja, A., Chappell, A. E., Prakash, T. P., Norrbom, M., Swayze, E. E., Leumann, C. J., & Seth, P. P. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks273 · Cited by 95
Li, S., Chen, T., Zhong, Z., Wang, Y., Li, Y., & Zhao, X. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.779 · Cited by 86
“Two anti-miR-122 oligonucleotides have been proven to be specific, stable and non-toxic in two primate studies (25,26).”
The Role of microRNAs in Metabolic Syndrome-Related Oxidative Stress
Włodarski, A., Strycharz, J., Wróblewski, A. M., Kasznicki, J., Drzewoski, J., & Śliwińska, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186902 · Cited by 107
Goldaracena, N., Spetzler, V. N., Echeverri, J. A., Kaths, J. M., Cherepanov, V., Persson, R., Hodges, M. R., Janssen, H. L. A., Selzner, N., Grant, D. R., et al. (2016) · American Journal of Transplantation · doi:10.1111/ajt.14100 · Cited by 88
“Longer-term follow-up studies in chimpanzees have not shown complications associated with temporary miR-122 silencing (30).”
Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma
Amodio, N., Martino, M. T. D., Neri, A., Tagliaferri, P., & Tassone, P. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.796356 · Cited by 83
RNAi Therapeutic Platforms for Lung Diseases
Fujita, Y., Takeshita, F., Kuwano, K., & Ochiya, T. (2013) · Pharmaceuticals · doi:10.3390/ph6020223 · Cited by 97
“An LNA-antimiR against miR-122 has been shown to effectively silence miR-122 in non-human primates [145], and the findings support the potential of these compounds as a new class of therapeutics.”
BackgroundmicroRNAs in skeletal muscle differentiation and disease
Goljanek‐Whysall, K., Sweetman, D., & Münsterberg, A. (2012) · Clinical Science · doi:10.1042/cs20110634 · Cited by 97
Xia, H., & Hui, K. M. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.58 · Cited by 83
MicroRNA Silencing in Primates: Towards Development of Novel Therapeutics
Petri, A., Lindow, M., & Kauppinen, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2749 · Cited by 74
“Moreover, we observed no changes in blood coagulation profiles of LNAantimiR–treated monkeys and no abnormalities in histopathologic investigations of the primate liver biopsies ( 10 ).”
BackgroundInfluentialSelf-citationMicroRNAs at the Interface between Osteogenesis and Angiogenesis as Targets for Bone Regeneration
Fröhlich, L. (2019) · Cells · doi:10.3390/cells8020121 · Cited by 97
“By using specific LNA (locked nucleic acids)-based antimiRs as well as miR-92a-deficient ECs in the mouse, they found enhanced re-endothelialization and inhibited neointimal formation induced by de-repression of the miR-92a targets integrin a5 and sirt1 [179].”
BackgroundGriveau, A., Béjaud, J., Anthiya, S., Avril, S., Autret, D., & Garcion, E. (2013) · International journal of pharmaceutics · doi:10.1016/j.ijpharm.2013.05.049 · Cited by 80
“As a matter of fact, the first human phase II miRNAbased therapy was developed in 2010 for hepatitis C and use LNAs synthesized as unconjugated LNA/DNA mixmers (miravirsen, SPC3649, LNA-antimiRTM-122, Santaris Pharma) (Elmen et al., 2008; Lanford et al., 2009).”
BackgroundBaselga‐Escudero, L., Arola‐Arnal, A., Pascual‐Serrano, A., Ribas‐Latre, A., Casanova, E., Salvadó, M. J., Arola, L., & Bladé, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069817 · Cited by 86
“Moreover, gene silencing of miR122 in mice [9,10], African green monkeys [11] and chimpanzees [12], using either antagomirs or antisense oligonucleotides, significantly decrease plasma cholesterol and TG levels.”
BackgroundThe Therapeutic Potential of MicroRNAs: Disease Modulators and Drug Targets
McDermott, A. M., Heneghan, H., Miller, N., & Kerin, M. J. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0550-2 · Cited by 78
“Hepatitis C virus miR-122 n/a In vivo (24,26)”
BackgroundmicroRNAs and lung cancer: tumors and 22-mers
Du, L., & Pertsemlidis, A. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9204-9 · Cited by 86
“[139], supporting the development of these approaches in the clinical setting.”
Antisense Oligonucleotide-Based Therapies for Diseases Caused by pre-mRNA Processing Defects
Rigo, F., Seth, P. P., & Bennett, C. F. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-1221-6_9 · Cited by 80
Regulation of alveolar septation by microRNA-489.
Olave, N., Lal, C., Halloran, B., Pandit, K., Cuna, A., Faye-Petersen, O., Kelly, D., Nicola, T., Benos, P., Kaminski, N., et al. (2016) · American Journal of Physiology - Lung cellular and Molecular Physiology · doi:10.1152/ajplung.00145.2015 · Cited by 79
“Mice were treated daily from 4 to 14 days of age by intranasal administration of LNA Mus musculus (mmu)-miR-489 corresponding to 5 g·g (1)·day 1 dissolved in 5 l water (16).”
BackgroundMethodEmerging Roles for MicroRNAs in Perioperative Medicine
Neudecker, V., Brodsky, K. S., Kreth, S., Ginde, A. A., & Eltzschig, H. K. (2015) · Anesthesiology · doi:10.1097/aln.0000000000000969 · Cited by 91
Bernardo, B., Gao, X.-M., Tham, Y., Kiriazis, H., Winbanks, C. E., Ooi, J., Boey, E. J. H., Obad, S., Kauppinen, S., Gregorevic, P., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090337 · Cited by 79
“miRNA inhibitors or antimiRs have been shown to be efficient in silencing miRNAs in mice [7], and non-human primates [8], and the first miRNAtargeted drug, miravirsen, has advanced into clinical phase 2 trials for the treatment of hepatitis C virus infection [9].”
BackgroundSelf-citationTakwi, A., Wang, Y.-M., Wu, J., Michaelis, M., Cinatl, J., & Chen, T.-S. (2013) · Oncogene · doi:10.1038/onc.2013.330 · Cited by 79
MicroRNAs as pharmacological targets in diabetes
Mao, Y., Mohan, R., Zhang, S., & Tang, X. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.06.005 · Cited by 91
MicroRNAs in breast cancer initiation and progression
Liu, H. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1128-9 · Cited by 87
Targeting miRNAs in osteoblast differentiation and bone formation
Hu, R., Li, H., Liu, W., Yang, L., Tan, Y., & Luo, X. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.512916 · Cited by 77
“Effective in vivo knockdown using LNA and phosphorothioate-modified oligonucleotides has been demonstrated in mice and non-human primates [110].”
BackgroundMicroRNAs in the tumor endothelium: Novel controls on the angioregulatory switchboard
Heusschen, R., van Gink, M., Griffioen, A. W., & Thijssen, V. L. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.09.005 · Cited by 73
Epigenetic modifications in rheumatoid arthritis
Strietholt, S., Maurer, B., Peters, M. A., Pap, T., & Gay, S. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2500 · Cited by 77
“That this aim is not beyond the realm of possibility is supported by the successful and well-tolerated use of antimiRs in rodents [48,64] as well as in non-human primates [65].”
BackgroundElhanati, S., Ben-Hamo, R., Kanfi, Y., Varvak, A., Glazz, R., Lerrer, B., Efroni, S., & Cohen, H. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.023 · Cited by 77
Oxidative stress in atherosclerosis: The role of microRNAs in arterial remodeling
Zampetaki, A., Dudek, K., & Mayr, M. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.06.025 · Cited by 80
“These findings were extended to nonhuman primates, in which antagonism of miR-122 in African green monkeys led to significantly lower cholesterol in the circulation without apparent toxicity [75].”
Teng, Y., Mei, Y., Hawthorn, L., & Cowell, J. K. (2013) · Oncogene · doi:10.1038/onc.2012.565 · Cited by 87
“These LNAs inhibit function of the miRNA through high affinity binding to their targets (24).”
BackgroundRNAcentral: A vision for an international database of RNA sequences.
Bateman, A., Agrawal, S., Birney, E., Bruford, E., Bujnicki, J., Cochrane, G., Cole, J., Dinger, M., Enright, A., Gardner, P., et al. (2011) · RNA: A publication of the RNA Society · doi:10.1261/rna.2750811 · Cited by 77
Role and therapeutic potential of microRNAs in diabetes
Kolfschoten, I., Roggli, E., Nesca, V., & Regazzi, R. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01118.x · Cited by 79
Yin Yang 1 is a target of microRNA-34 family and contributes to gastric carcinogenesis
Wang, A.-M., Huang, T.-T., Hsu, K.-W., Huang, K.-H., Fang, W.-L., Yang, M.-H., Lo, S., Chi, C., Lin, J.-J., & Yeh, T.-S. (2014) · OncoTarget · doi:10.18632/oncotarget.2073 · Cited by 76
Kalani, A., Kamat, P. K., Familtseva, A., Chaturvedi, P., Muradashvili, N., Narayanan, N., Tyagi, S. C., & Tyagi, N. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.74 · Cited by 73
MicroRNAs in Hepatocellular Carcinoma: Carcinogenesis, Progression, and Therapeutic Target
Hung, C., Chiu, Y., Chen, C., & Hu, T. (2014) · BioMed Research International · doi:10.1155/2014/486407 · Cited by 78
“Previous studies have demonstrated that inhibition of miR122 by administration of anti-miRNA oligonucleotides in nonhuman primates is a promising approach for reducing miRNA activity in the adult liver without toxicity [129].”
BackgroundRetractedMicroRNAs in the pathophysiology and treatment of status epilepticus
Henshall, D. C. (2013) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2013.00037 · Cited by 72
Fractionated Radiation Alters Oncomir and Tumor Suppressor miRNAs in Human Prostate Cancer Cells
John-Aryankalayil, M., Palayoor, S. T., Makinde, A. Y., Cerna, D., Simone, C. B., Falduto, M. T., Magnuson, S. R., & Coleman, C. N. (2012) · Radiation Research · doi:10.1667/rr2703.1 · Cited by 75
miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy
Sasaki, K., Kohanbash, G., Hoji, A., Ueda, R., McDonald, H. A., Reinhart, T. A., Martinson, J. J., Lotze, M. T., Marincola, F. M., Wang, E., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-17 · Cited by 80
“[15].”
microRNAs: tiny regulators of synapse function in development and disease
Bicker, S., & Schratt, G. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00400.x · Cited by 71
“In a recent study, it was demonstrated that LNA-antimiRs can safely and efficiently silence a miRNA in non-human primates [103].”
BackgroundDevelopment of MicroRNAs as Potential Therapeutics against Cancer
Abd-Aziz, N., Kamaruzman, N. I., & Poh, C. L. (2020) · Journal of Oncology · doi:10.1155/2020/8029721 · Cited by 97
“LNA-modified antisense oligonucleotides were able to display higher thermal stability and affinity with their miRNA target molecules, had higher aqueous solubility, and increased metabolic stability for in vivo delivery [67].”
BackgroundHypoxamiRs: regulators of cardiac hypoxia and energy metabolism.
el Azzouzi, H., Leptidis, S., Doevendans, P., & de Windt, L. D. (2015) · Trends in endocrinology and metabolism · doi:10.1016/j.tem.2015.06.008 · Cited by 74
“Indeed, LNA-protected antimirs possess the thermodynamically strongest duplex formation with complementary target RNA of all antimirs, show excellent mismatch discrimination, and show lack of toxicity in nonhuman primates [69,70].”
Aberrant microRNA expression and its implications in the pathogenesis of leukemias
Babashah, S., Sadeghizadeh, M., Rezaei–Tavirani, M., Farivar, S., & Soleimani, M. (2012) · Cellular Oncology · doi:10.1007/s13402-012-0095-3 · Cited by 76
TargetingmiR-205in breast cancer
Wu, H., & Mo, Y. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903338777 · Cited by 71
“For example, LNA DNA oligos have been widely used to suppress specific microRNAs [100].”
BackgroundPapapetrou, E. P., Korkola, J. E., & Sadelain, M. (2010) · Stem Cells · doi:10.1002/stem.257 · Cited by 73
New Progress in Early Diagnosis of Atherosclerosis
Meng, H., Ruan, J., Yan, Z., Chen, Y., Liu, J., Li, X., & Meng, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168939 · Cited by 92
“MiR-122 is a critical regulator of cholesterol and fatty acid production and hence a crucial regulator of lipoprotein homeostasis, as shown by tests in mice and non-human primates, where its function was inhibited [43,44].”
BackgroundDual Role of MicroRNAs in NAFLD
Ceccarelli, S., Panera, N., Gnani, D., & Nobili, V. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14048437 · Cited by 67
Yahara, A., Shrestha, A. R., Yamamoto, T., Hari, Y., Osawa, T., Yamaguchi, M., Nishida, M., Kodama, T., & Obika, S. (2012) · ChemBioChem · doi:10.1002/cbic.201200506 · Cited by 85
MicroRNAs in atherosclerosis and lipoprotein metabolism
Vickers, K. C., & Remaley, A. T. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32833727a1 · Cited by 75
Ma, L. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.07.004 · Cited by 76
The Role of MicroRNAs in Viral Infection
Roberts, A. P. E., Lewis, A., & Jopling, C. L. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-415795-8.00002-7 · Cited by 90
miRNA142-3p targets Tet2 and impairs Treg differentiation and stability in models of type 1 diabetes
Scherm, M. G., Serr, I., Zahm, A. M., Schug, J., Bellusci, S., Manfredini, R., Salb, V. K., Gerlach, K., Weigmann, B., Ziegler, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13587-3 · Cited by 87
Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles
Shin, H., Park, S. D., Yim, Y., Kim, J., Choi, C., Won, C., & Min, D. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800065 · Cited by 100
Solid tumors of childhood display specific serum microRNA profiles
Murray, M., Raby, K., Saini, H., Bailey, S., Wool, S., Tunnacliffe, J. M., Enright, A., Nicholson, J., & Coleman, N. (2014) · Cancer Epidemiology, Biomarkers and Prevention · doi:10.1158/1055-9965.epi-14-0669 · Cited by 72
Fujiwara, T., Katsuda, T., Hagiwara, K., Kosaka, N., Yoshioka, Y., Takahashi, R., Takeshita, F., Kubota, D., Kondo, T., Ichikawa, H., et al. (2013) · Stem Cells · doi:10.1002/stem.1618 · Cited by 79
All’s well that transcribes well: Non-coding RNAs and post-stroke brain damage
Vemuganti, R. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.07.014 · Cited by 71
“Systemic administration of antagomiR-122 modified with the locked nucleic acid chemistry was also shown to silence the miR-122 in non-human primates and this compound entered Phase II clinical trials (Elmen et al., 2008b; Haussecker and Kay, 2010).”
BackgroundStrategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury
Lee, T. J., Yuan, X., Kerr, K. M., Yoo, J. Y., Kim, D., Kaur, B., & Eltzschig, H. K. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.019026 · Cited by 80
“Elmen et al. (2008) systemically injected LNA-anti-miRs against miR-122 to nonhuman primates (African green monkeys) and observed successful uptake of the LNA-anti-miR-122 in hepatocytes and depletion of endogenous miR-122 through stable heteroduplexes formed between the LNA-anti-miR-122 and…”
BackgroundAnti-tumor Activity of miniPEG-γ-Modified PNAs to Inhibit MicroRNA-210 for Cancer Therapy
Gupta, A., Quijano, E., Liu, Y., Bahal, R., Scanlon, S. E., Song, E., Hsieh, W.-C., Braddock, D. T., Ly, D. H., Saltzman, W. M., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.09.001 · Cited by 83
The therapeutic potential of miRNAs regulated in settings of physiological cardiac hypertrophy.
Ooi, J., Bernardo, B., & McMullen, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.196 · Cited by 71
Binding of a Structured d -RNA Molecule by an l -RNA Aptamer
Sczepanski, J. T., & Joyce, G. F. (2013) · Journal of the American Chemical Society · doi:10.1021/ja406634g · Cited by 90
Cancer therapy via modulation of micro RNA levels: a promising future
Kota, S. K., & Balasubramanian, S. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.07.003 · Cited by 79
Jiang, H., Zhang, J., Du, Y., Jia, X., Yang, F., Si, S., Wang, L., & Hong, B. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.10.026 · Cited by 70
Heart failure: advances through genomics
Creemers, E., Wilde, A., & Pinto, Y. (2011) · Nature reviews genetics · doi:10.1038/nrg2983 · Cited by 70
The hunting of targets: challenge in miRNA research
Moqadam, F. A., Pieters, R., & den Boer, M. L. (2012) · Leukemia · doi:10.1038/leu.2012.179 · Cited by 77
The Liver-Specific MicroRNA miR-122: Biology and Therapeutic Potential
Filipowicz, W., & Großhans, H. (2010) · Springer eBooks · doi:10.1007/978-3-7643-8989-5_11 · Cited by 78
“The HCV virus does not infect mouse cells and there is no rodent model available for studies of hepatitis C. However, effects of anti-miR122 antagomirs were more recently investigated in nonhuman primates, i.e., African green monkeys [ 62 ] and chimpanzees [63], with the latter being susceptible to chronic infection w…”
BackgroundMethodTissue and circulating microRNA influence reproductive function in endometrial disease
Louise Hull, M., & Nisenblat, V. (2013) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2013.07.012 · Cited by 69
THE ROLE OF MIR-212 AND INOS IN ALCOHOL-INDUCED INTESTINAL BARRIER DYSFUNCTION AND STEATOHEPATITIS
Tang, Y.-M., Zhang, L.-J., Forsyth, C., Shaikh, M., Song, S.-W., & Keshavarzian, A. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12813 · Cited by 69
“This is consistent with previous reports that LNA-anti-miRNAs efficiently silenced miRNAs in mice (Elmen et al., 2008; Krutzfeldt et al., 2007).”
BackgroundMethodResultInfluentialThe role of miRNAs in Cancer: From Pathogenesis to Therapeutic Implications
Seven, M., Karataş, Ö. F., Düz, M. B., & Özen, M. (2014) · Future Oncology · doi:10.2217/fon.13.259 · Cited by 71
Concise Review: MicroRNAs as Modulators of Stem Cells and Angiogenesis
Kane, N. M., Thrasher, A. J., Angelini, G. D., & Emanueli, C. (2014) · Stem Cells · doi:10.1002/stem.1629 · Cited by 74
Potential therapeutic role of microRNAs in ischemic heart disease
Caroli, A., Cardillo, M. T., Galea, R., & Biasucci, L. M. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.01.012 · Cited by 75
Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges
Kwekkeboom, R. F. J., Lei, Z., Doevendans, P. A., Musters, R. J. P., & Sluijter, J. P. G. (2014) · Clinical Science · doi:10.1042/cs20140005 · Cited by 81
Nucleic acid therapeutics: basic concepts and recent developments
Sharma, V. K., Rungta, P., & Prasad, A. K. (2014) · RSC Advances · doi:10.1039/c3ra47841f · Cited by 91
miRNAs as potential therapeutic targets for age-related macular degeneration
Wang, S., Koster, K. M., He, Y., & Zhou, Q. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.11.176 · Cited by 67
Therapeutic Targeting of microRNAs in Cancer: Future Perspectives
Tutar, L., Tutar, E., Özgür, A., & Tutar, Y. (2015) · Drug Development Research · doi:10.1002/ddr.21273 · Cited by 72
MicroRNAs in cancers and neurodegenerative disorders
Saito, Y., & Saito, H. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00194 · Cited by 63
Overexpression of microRNA-1 impairs cardiac contractile function by damaging sarcomere assembly.
Ai, J., Zhang, R., Gao, X., Niu, H.-F., Wang, N.-Z., Xu, Y., Li, Y., Ma, N., Sun, L.-H., Pan, Z.-W., et al. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs196 · Cited by 67
“To verify the specificity and the reversibility of miR-1 actions on cardiac contractile function, we treated the Tg mice with LNAmodified miR-1 antisense oligonucleotide (LNA-antimiR-1), a technique that has been shown to efficiently knockdown target miRNAs with long-lasting efficacy under in vivo condition.(36) The r…”
MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention
Karmakar, S., Kaushik, G., Nimmakayala, R. K., Rachagani, S., Ponnusamy, M. P., & Batra, S. K. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.020 · Cited by 78
“This restriction in conformation increases hybridization affinity towards complementary target, single-stranded RNA, and has been proven both in vitro and in vivo [78,80,81].”
Caporarello, N., Lupo, G., Olivieri, M., Cristaldi, M., Cambria, M. T., Salmeri, M., & Anfuso, C. D. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7179 · Cited by 84
“…improve specificity and stability and ⅲ) miR-mask: modified 2'-O-methyl oligonucleotide complementary to the miRNA binding sites on the target mRNA (91-93). miRNAs can act as positive or negative modulators and bind to a plethora of different targets, thus the same miRNA can cause the opposite…”
Transcribed ultraconserved region in human cancers
Peng, J.-C., Shen, J., & Ran, Z. (2013) · RNA Biology · doi:10.4161/rna.26995 · Cited by 66
“An ASO that targeted miR-122 induced the inhibition of its function and decreased plasma cholesterol level.(28) lncRNA BACE1-AS was identified as upregulated in Alzheimer disease.”
BackgroundmiR-29b represses intestinal mucosal growth by inhibiting translation of cyclin-dependent kinase 2
Xiao, L., Rao, J. N., Zou, T., Liu, L., Cao, S., Martindale, J. L., Su, W., Chung, H. K., Gorospe, M., & Wang, J. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-05-0287 · Cited by 69
“Consistent with studies from others (Esau et al., 2006; Elmen et al., 2008), systemic”
MethodTissular and soluble miRNAs for diagnostic and therapy improvement in digestive tract cancers
Albulescu, R., Neagu, M. T., Albulescu, L., & Tănase, C. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.106 · Cited by 62
Andersen, D. C., Jensen, C. H., Schneider, M., Nossent, A. Y., Eskildsen, T. V., Hansen, J. L., Teisner, B., & Sheikh, S. P. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.04.002 · Cited by 77
“Anti-miRs were from Integrated DNA Technologies, and designed in accordance with previously validated LNA-based anti-miRs [48] (Scramble, 5'-+T*G*+T*A*A*+C*+A*C*G*+T*C*+T*A*+ T*+A-3'; anti-miR-15a, 5'-+C*C*+A*T*T*+A*+T*G*T*+G*C*+ T*G*+C*+T-3'; anti-miR-103, 5'-+C*C*+T*G*T*+A*+C*A*A*+”
Strategies to target long non-coding RNAs in cancer treatment: progress and challenges
Dizaji, B. F. (2020) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-020-00074-4 · Cited by 83
Valdmanis, P. N., Kim, H. K., Chu, K., Zhang, F., Xu, J., Munding, E. M., Shen, J., & Kay, M. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07786-7 · Cited by 72
Circulating microRNAs as biomarkers for metabolic disease
Párrizas, M., & Novials, A. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.08.001 · Cited by 74
MicroRNA‐130a inhibits HCV replication by restoring the innate immune response
Li, S., Duan, X., Li, Y., Liu, B., McGilvray, I., & Chen, L. (2014) · Journal of Viral Hepatitis · doi:10.1111/jvh.12131 · Cited by 65
Kreth, S., Thon, N., & Kreth, F. W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.008 · Cited by 75
“Basically, two approaches exist: first, suppression of disease-specific miRNAs, and second, application of specificmiRNAs in excess to the diseased tissue or organism to achieve therapeutic effects by selective gen silencing [122–124].”
BackgroundRNAi Therapeutics and Applications of MicroRNAs in Cancer Treatment
Uchino, K., Ochiya, T., & Takeshita, F. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt052 · Cited by 63
Niu, H., Wang, K., Zhang, A., Yang, S., Song, Z., Wang, W. T., QIAN, C., Li, X., Zhu, Y., & Wang, Y. (2012) · Oncology Reports · doi:10.3892/or.2012.1970 · Cited by 60
“Recent studies have developed a novel, molecularly-targeted, multimodal therapeutic approach with the use of antisense ‘antagomir’ oligonucleotides (5), which may enable development of novel cancer therapies. miRNAs are small, evolutionary conserved RNA molecules that control gene expression…”
Molecular Pathogenesis of Pancreatic Cancer and Clinical Perspectives
Matthaios, D., Zarogoulidis, P., Balgkouranidou, I., Chatzaki, Ε., & Kakolyris, S. (2011) · Oncology · doi:10.1159/000334449 · Cited by 66
Graziewicz, M., Tarrant, T., Buckley, B., Roberts, J., Fulton, L. M., Hansen, H., Ørum, H., Kole, R., & Sazani, P. (2008) · Molecular Therapy · doi:10.1038/mt.2008.85 · Cited by 65
Self-citationLong Non-coding RNA DANCR as an Emerging Therapeutic Target in Human Cancers
Jin, S.-J., Jin, M., Xia, B.-R., & Jin, W. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01225 · Cited by 73
Dysregulation of mi RNA and its potential therapeutic application in schizophrenia
Cao, T., & Zhen, X. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12840 · Cited by 77
Grijalvo, S., Alagia, A., Jorge, A. F., & Eritja, R. (2018) · Genes · doi:10.3390/genes9020074 · Cited by 79
“who engineered a 15-mer oligonucleotide containing LNAs (>50%) which was entirely modified with phosphorothioate residues targeting miR-122 expression [187].”
BackgroundMicroRNAs and vascular (dys)function
Hartmann, D., & Thum, T. (2011) · Vascular Pharmacology · doi:10.1016/j.vph.2011.07.005 · Cited by 74
Boutz, D. R., Collins, P. J., Suresh, U., Lu, M., Ramírez, C. M., Fernandez-Hernando, C. F., Huang, Y., Abreu, R. D. S., Le, S., Shapiro, B. A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.196451 · Cited by 66
Silencing microRNA by interfering nanoparticles in mice
Su, J., Baigude, H., McCarroll, J. A., & Rana, T. M. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1307 · Cited by 71
Kovalchuk, O., Zemp, F., Filkowski, J., Altamirano, A. M., Dickey, J., Jenkins-Baker, G., Marino, S., Brenner, D., Bonner, W., & Sedelnikova, O. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq119 · Cited by 64
Metadata
- Authors
- Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., Gullans, S., Kearney, P., Sarnow, P., Straarup, E. M., & Kauppinen, S.
- Affiliations
- Stanford Medicine (US)
- University of Copenhagen (DK)
- Corresponding author
- Kauppinen, Sakari
- Venue
- Nature
- Published
- 2008-03-26
- Volume
- 452
- Issue
- 7189
- Pages
- 896-899
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142310248
- Cited by
- 1,589
- References
- 0
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 23 · 2023: 23 · 2022: 54 · 2021: 48 · 2020: 63 · 2019: 66 · 2018: 62 · 2017: 75 · 2016: 100 · 2015: 113 · 2014: 139 · 2013: 176 · 2012: 175
- FWCI
- 60.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- microRNA silencing, locked nucleic acid, miR-122, cholesterol lowering, vervet monkey, non-human primates, hepatocyte uptake, heteroduplex formation, serum cholesterol, siRNA, oligonucleotide toxicity, gene expression regulation, drug target validation
- MeSH terms
- Animals, Chlorocebus aethiops, Female, Mice, Inbred C57BL, Oligonucleotides, Gene Silencing, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.